Warning! GuruFocus detected
1 Severe warning sign
with TMDX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
TransMedics Group Inc
NAICS : 334510
SIC : 3845
ISIN : US89377M1099
Description
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.65 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 2.27 | |||||
| Debt-to-EBITDA | 7.41 | |||||
| Interest Coverage | 2.6 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.04 | |||||
| Beneish M-Score | -2.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 125.3 | |||||
| 3-Year FCF Growth Rate | -25.1 | |||||
| 3-Year Book Growth Rate | 40.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 42.86 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 19.12 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.18 | |||||
| 9-Day RSI | 57.54 | |||||
| 14-Day RSI | 53.97 | |||||
| 3-1 Month Momentum % | 14.24 | |||||
| 6-1 Month Momentum % | -50.77 | |||||
| 12-1 Month Momentum % | 2.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.3 | |||||
| Quick Ratio | 7.52 | |||||
| Cash Ratio | 5.62 | |||||
| Days Inventory | 97.69 | |||||
| Days Sales Outstanding | 68.53 | |||||
| Days Payable | 23.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | -4.84 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.36 | |||||
| Operating Margin % | 8.49 | |||||
| Net Margin % | 8.03 | |||||
| FCF Margin % | -18.33 | |||||
| ROE % | 19.17 | |||||
| ROA % | 4.69 | |||||
| ROIC % | 10.65 | |||||
| 3-Year ROIIC % | 19.52 | |||||
| ROC (Joel Greenblatt) % | 15.09 | |||||
| ROCE % | 7.17 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 70.09 | |||||
| Forward PE Ratio | 48.34 | |||||
| PE Ratio without NRI | 71.15 | |||||
| PS Ratio | 5.64 | |||||
| PB Ratio | 10.41 | |||||
| Price-to-Tangible-Book | 11.08 | |||||
| Price-to-Operating-Cash-Flow | 51.16 | |||||
| EV-to-EBIT | 51.55 | |||||
| EV-to-EBITDA | 36.99 | |||||
| EV-to-Forward-EBITDA | 21.6 | |||||
| EV-to-Revenue | 5.86 | |||||
| EV-to-Forward-Revenue | 4.77 | |||||
| EV-to-FCF | -31.97 | |||||
| Price-to-GF-Value | 0.32 | |||||
| Price-to-Graham-Number | 5.92 | |||||
| Earnings Yield (Greenblatt) % | 1.94 | |||||
| FCF Yield % | -3.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TMDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TransMedics Group Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 441.54 | ||
| EPS (TTM) ($) | 1.01 | ||
| Beta | 2.48 | ||
| 3-Year Sharpe Ratio | 0.88 | ||
| 3-Year Sortino Ratio | 1.78 | ||
| Volatility % | 85.04 | ||
| 14-Day RSI | 53.97 | ||
| 14-Day ATR ($) | 4.339023 | ||
| 20-Day SMA ($) | 69.192 | ||
| 12-1 Month Momentum % | 2.72 | ||
| 52-Week Range ($) | 55 - 177.37 | ||
| Shares Outstanding (Mil) | 33.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TransMedics Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TransMedics Group Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TransMedics Group Inc Frequently Asked Questions
What is TransMedics Group Inc(TMDX)'s stock price today?
The current price of TMDX is $70.79. The 52 week high of TMDX is $177.37 and 52 week low is $55.00.
When is next earnings date of TransMedics Group Inc(TMDX)?
The next earnings date of TransMedics Group Inc(TMDX) is 2025-04-30 Est..
Does TransMedics Group Inc(TMDX) pay dividends? If so, how much?
TransMedics Group Inc(TMDX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers